Hiru Corporation (HIRU)

[chuck44l]

HIRU-MindUp BioResearch (HIRU) Participates in the Fourth Conference of the Translati

--------------------------------------------------------------------------------

MindUp BioResearch (HIRU) Participates in the Fourth Conference of the Translational Cancer Medicine 2010 (USA), San Francisco, California

Press Release Source: Hiru Corporation On Wednesday February 9, 2011, 1:00 pm
BELGRADE, SERBIA--(Marketwire - 02/09/11) - Hiru Corporation (PINK SHEETS:HIRU - News) (http://www.hirucorporation.com/), is pleased to announce that researchers from its MindUp BioResearch (www.mindupbioresearch.com), European subsidiary have presented their results at the fourth Conference of the Translational Cancer Medicine 2010 (USA), held in San Francisco, California, July 11-14, 2010, under the auspices of American Association for Cancer Research (AACR). The AACR (http://www.aacr.org) is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Dr Sabera Ruzdijic, the Leader of MindUp Bioresearch Group said: "Translational research is a key programmatic priority of the American Association for Cancer Research, and this fourth conference in the Translational Cancer Medicine Conference Series was developed with this in mind. This international conference was an excellent opportunity to get insight into the current advances in translational cancer medicine, and new collaborations were fostered through the open discourse essential for progress against cancer. We were pleased that we were able to present our latest results on investigation of genomic basis of glioblastoma development, the most frequent and the most aggressive human brain tumors. We observed that p53 gene alteration could be an early event in tumor development, while PTEN gene inactivation and EGFR gene amplification may lead to tumor progression and therefore indicate a subgroup of patients with more aggressive disease. These results confirm the important role of these genes in development and predicting of this severe disease in central nervous system. Dr Jasna Bankovic, as a presenting author, had a long discussion with the visitors of our poster presentation answering all the questions on the topic presented."

Dr Sabera Ruzdijic added: "Translational cancer medicine takes place at the interface between the lab and the clinic. It transitions basic science breakthroughs to the practice of medicine and uses clinical outcome to feed back into basic research. Consecutively, to make any advances in translational cancer medicine, there must be open lines of communication between researchers and clinicians."

At the company website http://www.hirucorporation.com/ you can find the poster presented at the Conference.